ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SBFM / earnings
REVB (36) SILO (18) ELAB (27) APVO (35) ⌘ Pro Terminal →

Sunshine Biopharma Inc. (SBFM) Next Earnings Date & Expected ±12.5% Move

$2.75 -6.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.71

Sunshine Biopharma Inc. (SBFM) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SBFM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SBFM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Sunshine Biopharma Inc. (NASDAQ: SBFM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $2.75 (-6.14% 1D, market cap $2.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SBFM ranks #896 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SBFM compare to REVB and SILO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SBFM carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 33.8%, and ROIC of -21.4%. By comparison, REVB (Revelation Biosciences Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M) and SILO (Silo Pharma Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M). Among the 5-stock peer group, SBFM leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SBFM?
▼

Per SBFM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001402328), Sunshine Biopharma Inc. generated $36.3M in revenue (+4.1% YoY), -$6.0M in net income, and -$5.5M in free cash flow against $30.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.71 (-1.30%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510027
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (5)Whales (3)SEC (8)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-13.8% Base Target
$487 Bull$2 Base$2 Bear
📬 FREE SBFM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SBFM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY SBFM SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (22% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 28.8 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
35
Grade E$4.72-6.8% Next Q
Q2 (-2Q)
32
Grade E$4.40-32.7% Next Q
Q3 (-1Q)
30
Grade E$2.96-7.1% Next Q
Current
27
Grade E$2.75-10.3% Hist 90D α
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SBFM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SBFM currently carries a cautious 27/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.36) and Max Pain ($2.89) forces dealer call-delta covering toward $487.20.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SBFM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SBFM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.34 Expected Swing
$2.41 (-12.5%)Spot $2.75$3.09 (+12.5%)
MODEL EARNINGS SETUP GAUGE

SBFM Quantitative Pre-Earnings Setup: 27/100

Trailing EPS: $4.25 • YoY Revenue Growth: 4.1%

Model Bullish Setup (27/100)Model Risk Weight (73/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$36.3M-$6.0M-$5.5M33.8%
FY 20242024-12-31$34.9M-$5.1M-$14.2M30.6%
FY 20232023-12-31$24.1M-$4.5M-$8.8M33.8%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SBFM)

  • ✓Walkthrough of SBFM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SBFM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -98.75%⚡ TESTING RESISTANCE
2026-11-03O $3.33H $3.33L $2.75C $2.75VOL 114.2K
RES: $34.48SUP: $0.06SMA50: $13.36SMA200: $106.6
$496.3$362.5$228.7$94.86$-38.95RES $34.48SUP $0.06$2.752026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SBFM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SBFM Butterfly Map → + Track SBFM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +4.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SBFM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SBFM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SBFM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SBFM)

Health Care Rank #896 of 1015 ⚔️ REVB vs SBFM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SBFM vs. REVB, SILO, ELAB, APVO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Sunshine Biopharma Inc. (SBFM) ranks #896 by composite RQD confidence (27/100, grade E) and #991 by equity capitalization ($2.2M). Within this direct 5-issuer industry benchmark cohort, SBFM leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. REVB currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with SBFM at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SBFM ACTIVE
Sunshine Biopharma Inc.
E 27/100 — 33.8% -21.4% -6.14% $2.2M Benchmark Subject
REVB
Revelation Biosciences Inc.
D- 36/100 — — -35.0% +0.50% $2.3M /revb-vs-sbfm →
SILO
Silo Pharma Inc.
E 18/100 — 38.6% -35.0% -1.63% $2.3M /silo-vs-sbfm →
ELAB
PMGC Holdings Inc.
E 27/100 — 31.4% -35.0% -19.23% $2.1M /elab-vs-sbfm →
APVO
Aptevo Therapeutics Inc.
D- 35/100 — — -35.0% +0.75% $2.4M /apvo-vs-sbfm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001402328 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sunshine Biopharma Inc. (SBFM) reported GAAP revenue of $36.3M (+4.1% vs. FY2024 revenue of $34.9M , and +50.7% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$5.3M, and free cash flow of -$5.5M (+61.2% YoY). On the balance sheet, SBFM closed FY2025 with $30.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $36.3M -$6.0M -$5.3M -$5.5M $30.1M —
FY2024 (FY) 2024-12-31 $34.9M -$5.1M -$12.5M -$14.2M $30.6M —
FY2023 (FY) 2023-12-31 $24.1M -$4.5M -$8.8M -$8.8M — —

3. SBFM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SBFM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Sunshine Biopharma Inc. (NASDAQ: SBFM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $2.75 (-6.14% 1D, market cap $2.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SBFM ranks #896 in composite RQD confidence.

How does SBFM compare to REVB and SILO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SBFM carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 33.8%, and ROIC of -21.4%. By comparison, REVB (Revelation Biosciences Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M) and SILO (Silo Pharma Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M). Among the 5-stock peer group, SBFM leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SBFM?

Per SBFM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001402328), Sunshine Biopharma Inc. generated $36.3M in revenue (+4.1% YoY), -$6.0M in net income, and -$5.5M in free cash flow against $30.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SBFM trading relative to its 50-day, 200-day, and 52-week technical levels?

SBFM last traded at $2.75 (-6.14% on volume of 68,439 shares), positioning the stock -79.42% below its 50-day simple moving average ($13.36) and -97.42% below its 200-day simple moving average ($106.64). Across its 52-week range of $2.58 to $464.00, SBFM sits at the 0.0% percentile with a 14-day RSI of 28.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.41 to $3.09).

Direct Sub-Reports: SBFM RQD Cockpit SBFM 12M Forecast SBFM Earnings & Move SBFM Dividends & DRIP SBFM Insiders & 13F SBFM Whale Options SBFM Profit Sankey SBFM News & Why
ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

SBFM — Sunshine Biopharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Sunshine Biopharma Inc. (SBFM) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.75 (-6.14% 1D, market capitalization $2.2M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -21.4%, gross margin of 33.8%, operating margin of -17.2%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Sunshine Biopharma Inc. Is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..0B. The company reported revenue of $36.3M for FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Sunshine Biopharma Inc. (SBFM) reported $36.3M in annual revenue (up from $34.9M in FY2024, +4.1% YoY) and -$6.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.1M revenue, -$4.5M net income) through FY2025, SBFM scaled operating cash flow to -$5.3M and free cash flow to -$5.5M, backed by $30.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.58 – $464.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -17.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

For a prospective investor, the practical ripple to watch is dilution: repeated offerings and warrant issuance, as referenced in the news wire, can pressure per-share value independent of operating performance.

  • Key Question #1: Can SBFM sustain or expand its -17.2% operating margin and -21.4% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $36.3M and free cash flow of -$5.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SBFM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SBFM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sunshine Biopharma Inc. (SBFM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SBFM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SBFM Bull vs. Bear Conversation Board — What's Your Call at $2.75?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SBFM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SBFM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $3.72 (+27.0%)
📌 Pinned Debate

The stock's recent news flow points to new antiviral and generics product activity that could support a revenue narrative if it transla

The stock's recent news flow points to new antiviral and generics product activity that could support a revenue narrative if it translates into growth.. When you look under the hood at SBFM, Fundamental Cash Engine is 5/20 with 33.8% gross margins and -21.4% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $464.00. My 12M target is $3.72.

ArenaChamp_24 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (33.8%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $2.52 (-14.0%)
Spot @ $2.93

Repeated dilutive offerings and warrant issuance, alongside an Altman Z-Score of 0.2 and negative ROIC, signal significant financial di

Fading this rally in SBFM at $2.93. Repeated dilutive offerings and warrant issuance, alongside an Altman Z-Score of 0.2 and negative ROIC, signal significant financial distress and capital-raising risk.. With a beta of 1.0 and the stock sitting at $2.93 (52-wk range $2.58–$464.00), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%